Depressive Disorder News and Research

RSS

Individuals with mood disorders twice as likely to have heart attacks

Depression may have more far-reaching consequences than previously believed. Recent data suggests that individuals who suffer from a mood disorder could be twice as likely to have a heart attack compared to individuals who are not depressed.

29 Nov 2011

Deep brain stimulation benefits highly treatment resistant patients with major depressive disorder

Results from the first multi-center pilot study of deep brain stimulation (DBS) for major depressive disorder were published online today by the Journal of Neurosurgery. The study, conducted at three research facilities in Canada, was designed to replicate and build upon an earlier study by Dr. Andres Lozano and Dr. Helen Mayberg which was published in the journal Neuron in 2005.

18 Nov 2011

Higher protein load in critical brain regions linked to severe depression in late life

Depression is one of the most common mental disorders in the elderly, but little is known about the underlying biology of its development in older adults.

8 Nov 2011

Top-line results from AstraZeneca and Targacept's TC-5214 Phase 3 studies on MDD

AstraZeneca and Targacept, Inc. today announced top-line results from the first of four RENAISSANCE Phase 3 studies investigating the efficacy and tolerability of TC-5214 as an adjunct therapy to an antidepressant in patients with major depressive disorder (MDD) who do not respond adequately to initial antidepressant treatment.

8 Nov 2011

Rexahn announces results from Serdaxin Phase IIb trial on major depressive disorder

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced results from its Phase IIb clinical trial of Serdaxin in major depressive disorder.

5 Nov 2011

Vanda third quarter total revenues increase to $8.0 million

Vanda Pharmaceuticals Inc., a biopharmaceutical company focused on the development and commercialization of products for central nervous system disorders, today announced financial and operational results for the third quarter and nine months ended September 30, 2011.

4 Nov 2011

New e-tool to catch youth depression before it takes hold

Australian researchers will for the first time harness e-technology to develop a customised internet program to identify and arm healthy young people most at risk of depression before the illness takes hold.

1 Nov 2011

'Deep sequencing' technology identifies new target area for depression

Scientists at the Texas Biomedical Research Institute and Yale University have identified a new target area in the human genome that appears to harbor genes with a major role in the onset of depression.

29 Oct 2011

Future-Directed Therapy for patients with major depression

Patients with major depression do better by learning to create a more positive outlook about the future, rather than by focusing on negative thoughts about their past experiences, researchers at Cedars-Sinai say after developing a new treatment that helps patients do this.

20 Oct 2011

Forest Laboratories second quarter net sales increase 9.0% to $1,130.3 million

Forest Laboratories, Inc., an international pharmaceutical manufacturer and marketer, announced that reported earnings per share equaled $0.91 in the second quarter of fiscal 2012. Reported earnings per share in the second quarter of fiscal 2011 were $1.00.

18 Oct 2011

FDA approves NDA for Edgemont's Fluoxetine 60 mg tablet

Edgemont Pharmaceuticals, LLC, a neuroscience focused company, today announced that the U.S. Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for Fluoxetine Tablets 60 mg.

12 Oct 2011

Researchers discover molecular-level changes in brains of women with major depressive disorder

Researchers at the University of Pittsburgh School of Medicine have discovered molecular-level changes in the brains of women with major depressive disorder that link two hypotheses of the biological mechanisms that lead to the illness. Their results, published online this week in Molecular Psychiatry, also allowed them to recreate the changes in a mouse model that could enhance future research on depression.

17 Sep 2011

UTHealth to study BMS-820836 in Phase II trial for major depressive disorder

A new medication to treat major depressive disorder in patients who have not responded to other antidepressants is being studied in a Phase II clinical trial by researchers at The University of Texas Health Science Center at Houston.

2 Sep 2011

Daily exercise can work as well as second antidepressant drug

Exercise can be as effective as a second medication for as many as half of depressed patients whose condition have not been cured by a single antidepressant medication.

24 Aug 2011

Online brain training reduces depression, improves cognitive functions

CogniFit brain fitness program can improve cognitive functions of everyday living in individuals with depression.

18 Aug 2011

Positive results from levomilnacipran Phase III study for major depressive disorder

Forest Laboratories, Inc. and Pierre Fabre Medicament today announced preliminary top-line results from a Phase III study of levomilnacipran for the treatment of adults with major depressive disorder (MDD).

18 Jul 2011

Neuralstem receives U.S. patent allowance for three new neurogenic compounds

Neuralstem, Inc. announced that it has received notice of allowance for U.S. Patent Applications 12/939,897 and 12/939,914 entitled: "Compositions to Effect Neuronal Growth."

15 Jul 2011

Low optimism appears to predict initiation of psychotherapy

In a study published by a group of Finnish investigators headed by Prof. Karlsson in the current issue of Psychotherapy and Psychosomatics low level of optimism appear to predict initiation of psychotherapy for depression.

14 Jul 2011

FDA approves expansion of St. Jude Medical's BROADEN deep brain stimulation study for depression

St. Jude Medical, Inc., a global medical device company, today announced that the U.S. Food and Drug Administration (FDA) has granted approval for expansion of its BROADEN (BROdmann Area 25 DEep brain Neurostimulation) study for depression. This expansion will allow a maximum of 20 sites across the U.S. to enroll up to 125 patients.

11 Jul 2011

Enrollment complete in Rexahn's Serdaxin Phase IIb clinical trial for major depressive disorder

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced that it has completed enrollment in its Phase IIb clinical trial of Serdaxin to treat major depressive disorder (MDD).

22 Jun 2011